Breakthrough in the search for new treatments for multiple sclerosis

Scientists at The University of Nottingham have discovered a molecular mechanism which could bring about the development of new treatments for Multiple Sclerosis (MS) -- a chronic inflammatory disease of the central nervous system.

Dr Bruno Gran, a Clinical Associate Professor in the Division of Clinical Neurology in the School of Clinical Sciences, working in collaboration with Professor Paul Moynagh from the National University of Ireland, Maynooth, has discovered a synthetic which inhibits the pro-inflammatory signals produced by the immune system in MS. What makes this chemical unique is that at the same time, it stimulates the body to produce , an anti-inflammatory molecule, that is commonly given to patients as an injected drug to treat MS.

Together, these effects cause significant reduction in the severity of an of MS. The researchers have also discovered that cells of the immune system obtained from the blood of people with MS are more sensitive to the effects of this drug than those obtained from people who do not have MS.

Dr Gran said: "Under laboratory conditions we have found a way of encouraging the body to produce its own Interferon-beta. When other experimental substances have been tested in the laboratory to achieve this effect, they usually cause the immune system to produce a mixture of anti-inflammatory as well as pro-inflammatory molecules, typically reducing the overall efficacy. In the case of the compound tested in this study (a synthetic known as R(+)WIN55,212-2), the predominantly anti-inflammatory effects appear promising for further pre-clinical, and hopefully clinical, testing.

With no available cure MS is the focus of intense study for the hundreds of scientists across the world who are working on new treatments for this disabling disease. MS is more common in temperate climates. With around 100,000 people suffering from MS in the UK the country has one of the highest rates of the disease in the world.

Until 20 years ago there was little progress in the search for treatments.

After their first approval in 1993 Beta Interferons still represent one of the first line treatments for relapsing-remitting . These drugs are not a cure but they can reduce the number and severity of relapses. Despite this, more effective, well tolerated therapeutic strategies are needed.

Dr Gran's research continues a line of investigation which his laboratory has carried out for a number of years on the role of endogenous type I interferons in regulating multiple sclerosis inflammation in the .

The cause of MS is still something of a mystery. Numerous factors are thought to contribute, including genetic susceptibility and environmental factors. The latter are thought to include certain viral infections and low levels of vitamin D, linked to poor sun exposure.

These latest findings highlight a new selective mechanism that may be open to exploitation in the development of new therapeutics for the treatment of MS.

Related Stories

Best treatment for MS may depend on disease subtype

Jul 01, 2008

Animal studies by University of Michigan scientists suggest that people who experience the same clinical signs of multiple sclerosis (MS) may have different forms of the disease that require different kinds of treatment.

Hookworms in MS trial

Mar 03, 2009

Scientists from The University of Nottingham will study the potential health benefits of parasitic worms as part of a study investigating treatments for people with the autoimmune condition multiple sclerosis (MS).

Gene variant may increase severity of MS

Aug 02, 2010

A new study shows a gene variant may increase the severity of multiple sclerosis (MS) symptoms. The research will be published in the August 3, 2010, issue of Neurology, the medical journal of the American Academy of Neu ...

Recommended for you

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

ironjustice
not rated yet Jun 21, 2011
One might wonder if there is some connection between acetylcholine and interferon-beta. They have shown marijuana increases acetylcholine.
"Effects of cannabinoids on levels of acetylcholine and choline and on turnover rate of acetylcholine in various regions of the mouse brain."
"Cannabinoids increase ACh and decrease ACh turnover ."